<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383888</url>
  </required_header>
  <id_info>
    <org_study_id>1346.4</org_study_id>
    <nct_id>NCT02383888</nct_id>
  </id_info>
  <brief_title>Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Japanese and Chinese Male Subjects (Randomized, Double-blind, Placebo-controlled Design Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerability and pharmacokinetics of BI 425809 tablets in healthy&#xD;
      Chinese and Japanese male subjects following the administration of single rising oral doses&#xD;
      and further to explore the pharmacokinetics (PK) including dose proportionality of BI 425809&#xD;
      after single dosing of product.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of subjects with drug-related Adverse Events</measure>
    <time_frame>up to 18 days post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum measured concentration of the analyte in plasma</measure>
    <time_frame>up to 9 days post doing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>up to 9 days post doing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable plasma concentration</measure>
    <time_frame>up to 9 days post doing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from dosing to the maximum concentration of the analyte in plasma</measure>
    <time_frame>up to 9 days post doing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal half-life of the analyte in plasma</measure>
    <time_frame>up to 9 days post doing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Matching placebo for each dose groups</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 Active dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 Active dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bi 425809 Active dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <arm_group_label>BI 425809 Active dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <arm_group_label>Bi 425809 Active dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Matching placebo for each dose groups</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <arm_group_label>BI 425809 Active dose group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the investigator's assessment, based on a complete&#xD;
             medical history including a physical examination, vital signs (BP, PR), 12-lead ECG,&#xD;
             and clinical laboratory tests&#xD;
&#xD;
          -  Age 20 to 45 years (incl.)&#xD;
&#xD;
          -  BMI 18.5 to 25 kg/m2 (incl.)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
          -  Chinese ethnicity, Japanese ethnicity according to the following criteria:&#xD;
&#xD;
          -  Chinese: ethnic Chinese, born in China or ethnic Chinese born outside of China, and a&#xD;
             descendent of 4 ethnic Chinese grandparents who were all born in China&#xD;
&#xD;
          -  Japanese: born in Japan, have lived outside of Japan &lt;10 years, and have parents and&#xD;
             grandparents who were all born in Japan&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and judged clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure &lt;90 or &gt;140 mmHg, or diastolic blood&#xD;
             pressure &lt;50 or &gt;90 mmHg, or PR &lt;50 or &gt;90&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease judged clinically relevant by the investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial&#xD;
             medication&#xD;
&#xD;
          -  Diseases of the central nervous system (including by not limited to any kind of&#xD;
             seizures or stroke), other neurological disorders or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy/hypersensitivity (including allergy to the trial&#xD;
             medication or its excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10&#xD;
             half- lives of the respective drug prior to administration of trial medication&#xD;
&#xD;
          -  Within 10 days prior to administration of trial medication, use of drugs that might&#xD;
             reasonably influence the results of the trial or that might prolong the QT/QTc&#xD;
             interval&#xD;
&#xD;
          -  Participation in another trial with investigational drug administration within 60 days&#xD;
             prior to administration of trial medication&#xD;
&#xD;
          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)&#xD;
&#xD;
          -  Inability to refrain from smoking on specified trial days&#xD;
&#xD;
          -  Alcohol abuse (consumption of more than 20 g per day)&#xD;
&#xD;
          -  Drug abuse or positive drug screening&#xD;
&#xD;
          -  Blood donation of more than 100 mL within 30 days prior to administration of trial&#xD;
             medication or intended donation during the trial&#xD;
&#xD;
          -  Intention to perform excessive physical activities within one week prior to&#xD;
             administration of trial medication or during the trial&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
          -  At screening, a marked baseline prolongation of QT/QTcF interval (such as repeated&#xD;
             demonstration of a QTcF interval greater than 450 ms or any other relevant ECG finding&#xD;
&#xD;
          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,&#xD;
             hypokalemia, or family history of Long QT Syndrome)&#xD;
&#xD;
          -  Subject is assessed by the investigator as unsuitable for inclusion, for instance,&#xD;
             because considered not able to understand and comply with study requirements, or has a&#xD;
             condition that would not allow safe participation in the study&#xD;
&#xD;
          -  Male subjects who do not agree to minimize the risk of female partners becoming&#xD;
             pregnant from the first dosing day until two month after the study completion.&#xD;
             Acceptable methods of contraception comprises barrier contraception and a medically&#xD;
             accepted contraceptive method for the female partner (intra-uterine device with&#xD;
             spermicide, hormonal contraceptive since at least two month)&#xD;
&#xD;
          -  Evidence or history of macular degeneration or any abnormal finding in color&#xD;
             discrimination test, and any other clinically significant ophthalmic disorders based&#xD;
             on the investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1346.4.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 425809</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

